Recently, neutralizing autoantibodies against type I IFNs, mainly IFNA2 and IFNW1, have been identified in up to 13.7% of patients with life-threatening COVID-19 pneumonia, and were shown to be able to impair the capability to block the viral infection of the corresponding antibody43. Here, IFNA2 is linked to viral infectious disease.